BRPI0512742A - composto, composição farmacêutica, e, método de tratamento de uma doença, distúrbio e/ou condição em um paciente em que modulação de uma função 5-ht2c é desejada - Google Patents

composto, composição farmacêutica, e, método de tratamento de uma doença, distúrbio e/ou condição em um paciente em que modulação de uma função 5-ht2c é desejada

Info

Publication number
BRPI0512742A
BRPI0512742A BRPI0512742-4A BRPI0512742A BRPI0512742A BR PI0512742 A BRPI0512742 A BR PI0512742A BR PI0512742 A BRPI0512742 A BR PI0512742A BR PI0512742 A BRPI0512742 A BR PI0512742A
Authority
BR
Brazil
Prior art keywords
modulation
compounds
treating
disorder
disease
Prior art date
Application number
BRPI0512742-4A
Other languages
English (en)
Inventor
Youssef L Bennani
Michael J Robarge
David C Bom
Norbert Varga
Lawrence N Tumey
Original Assignee
Athersys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athersys Inc filed Critical Athersys Inc
Publication of BRPI0512742A publication Critical patent/BRPI0512742A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPOSTO, COMPOSIçãO FARMACêUTICA, E, MéTODO DE TRATAMENTO DE UMA DOENçA, DISTúRBIO E/OU CONDIçãO EM UM PACIENTE EM QUE MODULAçãO DE UMA FUNçãO 5-HT~2c~ é DESEJADA A presente invenção refere-se, de maneira geral, a uma série de compostos, a composições farmacêuticas que os contêm, e ao uso dos compostos e composições como agentes terapêuticos. Mais especificamente, compostos da presente invenção são compostos hexaidroazepinoindol e octaidroazepinoindol. Estes compostos são ligantes de receptor de serotonina (5HT) e são úteis para tratamento de doenças, distúrbios e condições em que é desejada a modulação da atividade de receptores de serotonina (5HT) (por exemplo, ansiedade, depressão e obesidade).Derivados de azepina substituída como moduladores de receptor de serotonina.
BRPI0512742-4A 2004-06-30 2005-06-29 composto, composição farmacêutica, e, método de tratamento de uma doença, distúrbio e/ou condição em um paciente em que modulação de uma função 5-ht2c é desejada BRPI0512742A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58491604P 2004-06-30 2004-06-30
PCT/US2005/023282 WO2006004931A2 (en) 2004-06-30 2005-06-29 Substituted azepine derivatives as serotonin receptor modulators

Publications (1)

Publication Number Publication Date
BRPI0512742A true BRPI0512742A (pt) 2008-04-15

Family

ID=35783355

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512742-4A BRPI0512742A (pt) 2004-06-30 2005-06-29 composto, composição farmacêutica, e, método de tratamento de uma doença, distúrbio e/ou condição em um paciente em que modulação de uma função 5-ht2c é desejada

Country Status (21)

Country Link
US (2) US7718647B2 (pt)
EP (1) EP1778243B1 (pt)
JP (1) JP5025469B2 (pt)
KR (1) KR101216984B1 (pt)
CN (1) CN1980710B (pt)
AR (1) AR049954A1 (pt)
AU (1) AU2005260636B2 (pt)
BR (1) BRPI0512742A (pt)
CA (1) CA2565683C (pt)
CY (1) CY1113559T1 (pt)
DK (1) DK1778243T3 (pt)
ES (1) ES2398694T3 (pt)
IL (1) IL179278A (pt)
NO (1) NO20070494L (pt)
NZ (1) NZ550891A (pt)
RU (1) RU2485125C2 (pt)
SI (1) SI1778243T1 (pt)
TW (1) TWI358410B (pt)
UA (1) UA88786C2 (pt)
WO (1) WO2006004931A2 (pt)
ZA (1) ZA200609234B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101503681B1 (ko) * 2006-01-19 2015-03-19 아더시스 인코포레이티드 세로토닌 5-ｈｔ2ｃ 수용체 리간드로서의 티오페닐 및 피롤릴 아제핀 및 이의 용도
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
US7897595B2 (en) 2006-05-26 2011-03-01 Forest Laboratories Holdings Limited Pyridoazepine derivatives
US8147315B2 (en) 2006-09-12 2012-04-03 Aristocrat Technologies Australia Ltd Gaming apparatus with persistent game attributes
CA2682377A1 (en) * 2007-03-30 2008-10-09 Nippon Shinyaku Co., Ltd. Heteroaryl derivatives
EP2789338A3 (en) 2007-11-15 2015-01-14 Takeda Pharmaceutical Company Limited Condensed pyridine derivate and use thereof
EP2510949A4 (en) 2009-12-11 2013-11-13 Astellas Pharma Inc THERAPEUTICS FOR FIBROMYALGIA
WO2011146089A1 (en) * 2010-05-21 2011-11-24 Abbott Laboratories Modulators of 5-ht receptors and methods of use thereof
TWI522361B (zh) * 2010-07-09 2016-02-21 艾伯維公司 作為s1p調節劑的稠合雜環衍生物
JP6198715B2 (ja) 2012-03-06 2017-09-20 武田薬品工業株式会社 三環性化合物
US9284277B2 (en) * 2012-12-21 2016-03-15 Abt Holding Company Benzazepines as serotonin 5-HT2C receptor ligands and uses thereof
US9309262B2 (en) 2013-03-13 2016-04-12 Abt Holding Company Thienylindole azepines as serotonin 5-HT2C receptor ligands and uses thereof
DE102013208337A1 (de) * 2013-05-07 2014-11-13 Henkel Ag & Co. Kgaa Aerosolzusammensetzung mit verbesserten Sprüheigenschaften
KR101917264B1 (ko) 2016-12-22 2018-11-13 한국과학기술연구원 5-ht7 수용체 조절제로 작용하는 아제핀 유도체
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU629879A3 (ru) * 1974-11-26 1978-10-25 Лилли Индастриз Лимитед, (Фирма) Способ получени тиено(1,5) бензодиазепинов или их солей
ZA821020B (en) * 1981-02-18 1983-10-26 Thomae Gmbh Dr K Azepine derivatives, process for their preparation and pharmaceutical compositions thereof
DE3230696A1 (de) * 1982-08-18 1984-02-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue thieno-thiazol-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB8800891D0 (en) 1988-01-15 1988-02-17 Lilly Industries Ltd Pharmaceutical compounds
GB9025890D0 (en) * 1990-11-28 1991-01-09 Lilly Industries Ltd Pharmaceutical compounds
ATE166047T1 (de) 1993-03-17 1998-05-15 Meiji Seika Co Neue verbindungen mit blutplättchenaggregationshemmender aktivität
EP0785939A1 (en) 1994-10-11 1997-07-30 Takeda Chemical Industries, Ltd. Substituted heterobicyclic alkyl amines and their use as squalene oxide cyclase inhibitors
JPH1165082A (ja) * 1997-08-11 1999-03-05 Fujitsu Ltd フォトマスク及び半導体装置の製造方法
US6369222B1 (en) * 2000-07-18 2002-04-09 Hoffmann-La Roche Inc. mGluR antagonists and a method for their synthesis
WO2002024700A2 (en) * 2000-09-20 2002-03-28 Pharmacia & Upjohn Company SUBSTITUTED AZEPINO[4,5b]INDOLINE DERIVATIVES
WO2002074746A1 (en) * 2001-03-16 2002-09-26 Yamanouchi Pharmaceutical Co., Ltd. Benzazepine derivatives
JP2003261566A (ja) * 2002-03-11 2003-09-19 Sankyo Co Ltd キノリジンを含有する医薬
US7452911B2 (en) * 2002-10-31 2008-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
ES2319539T3 (es) * 2003-09-17 2009-05-08 Janssen Pharmaceutica Nv Compuestos heterociclicos condensados como moduladores del receptor de serotonina.

Also Published As

Publication number Publication date
US20060003990A1 (en) 2006-01-05
AU2005260636B2 (en) 2011-04-14
SI1778243T1 (sl) 2013-03-29
DK1778243T3 (da) 2013-02-04
EP1778243B1 (en) 2012-10-31
NZ550891A (en) 2009-10-30
JP5025469B2 (ja) 2012-09-12
AU2005260636A1 (en) 2006-01-12
KR20070041544A (ko) 2007-04-18
RU2007103465A (ru) 2008-08-10
US20100190772A1 (en) 2010-07-29
NO20070494L (no) 2007-03-23
EP1778243A2 (en) 2007-05-02
WO2006004931A3 (en) 2006-04-13
IL179278A0 (en) 2007-03-08
JP2008505101A (ja) 2008-02-21
IL179278A (en) 2014-11-30
KR101216984B1 (ko) 2013-01-02
ZA200609234B (en) 2008-08-27
TW200611906A (en) 2006-04-16
ES2398694T3 (es) 2013-03-21
AR049954A1 (es) 2006-09-20
EP1778243A4 (en) 2009-09-30
CY1113559T1 (el) 2016-06-22
CN1980710B (zh) 2013-06-12
CN1980710A (zh) 2007-06-13
WO2006004931A2 (en) 2006-01-12
RU2485125C2 (ru) 2013-06-20
CA2565683C (en) 2013-04-02
CA2565683A1 (en) 2006-01-12
TWI358410B (en) 2012-02-21
US7718647B2 (en) 2010-05-18
UA88786C2 (ru) 2009-11-25

Similar Documents

Publication Publication Date Title
BRPI0512742A (pt) composto, composição farmacêutica, e, método de tratamento de uma doença, distúrbio e/ou condição em um paciente em que modulação de uma função 5-ht2c é desejada
KR101140510B1 (ko) 우울증 치료용 로티고틴의 용도
KR101160699B1 (ko) 우울증 치료용의 치환된 2-아미노테트라린
BRPI0512869A (pt) composto, composição farmacêutica, e, método de tratamento de uma doença, distúrbio e/ou condição em um paciente
BR112012014180A2 (pt) composto, composição farmacêutica, uso da composição farmacêutica, e, método para tratar uma doença ou em distúrbio.
BR112012022552A8 (pt) uso de fenoterol e de análogos de fenoterol no tratamento de gliobastomas e astrocitomas e composição farmacêutica compreendendo os referidos compostos
BRPI0518011A (pt) uso de tetraidrocanabidivarina, métodos para o tratamento de uma doença ou condição e para cosmeticamente beneficiar a perda de peso, e, uso de um antagonista do receptor de canabinóide neutro
Su et al. Agomelatine: a potential novel approach for the treatment of memory disorder in neurodegenerative disease
BR0307429A (pt) Composto, uso do mesmo, composição farmacêutica, e, método para o tratamento de distúrbios ou doenças relacionadas com receptor de histamina h3
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
BRPI0417156A (pt) composto, composição farmacêutica, e, métodos para bloquear receptor mu, capa, delta ou combinação (heterodìmero) dos mesmos em mamìferos, para tratar e/ou prevenir doenças relacionadas com obesidade e obesidade, para suprimir apetite em um paciente, para efetuar perda de peso em um paciente obeso
UA96447C2 (ru) Полиморфные формы (2s)-(4e)-n-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина для лечения расстройств центральной нервной системы
NO20082679L (no) Sammensetning og fremgangsmate for a behandle CNS lidelser
CL2011000137A1 (es) Uso de compuestos derivados de 4,5-dihidro-oxazol-2-ilamina para tratar trastornos de ansiedad, trastornos bipolar, esquizofrenia, enfermedades neurológicas, epilepsias, migraña, trastornos metabólicos, trastornos cardiovasculares, entre otros; compuestos derivados de 4,5-dihidroxazol-2-ilamino; proceso de síntesis
Descamps et al. Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep–wake cycle architecture
EA201000675A1 (ru) Производные хромана как модуляторы trpv3
Smith et al. Effect of SB-243213, a selective 5-HT2C receptor antagonist, on the rat sleep profile: a comparison to paroxetine
BR0316261A (pt) Composto, composição farmacêutica que compreende o mesmo, método para tratar uma enfermidade caracterizada por renovação, ativação, ou renovação e ativação de leucócitos patogênicos e método de antagonização de um receptor de quimioquinas c-c 1 em um paciente
TW200736189A (en) Indene derivatives, their preparation and use as medicaments
BRPI0517740A (pt) compostos n-sulfonilaminobenzil-2fenóxi acetamida substituìda
BR0213417A (pt) Compostos e composições de tetraciclicazaindóis e indolinas tendo atividade de 5-ht e seus usos
BRPI0512395A (pt) composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou a profilaxia de condições ou distúrbios associadas(os) com a modulação de receptor de estrogênio seletiva, e para o tratamento ou a profilaxia relacionado(a) com condições ou distúrbios
BRPI0516749A (pt) composições e métodos para tratamento de disturbìos cognitivos
BRPI0606402A2 (pt) moduladores de delta-opióide tricìclico
BRPI0415899A (pt) usos de um composto, e de um antagonista de receptor de h3, agonista inverso ou agonista parcial, composição farmacêutica, método para a identificação de compostos úteis para o tratamento de doenças, e, composto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]